Evidence map›Paper›PMID 24520372›Full record

ArticlePloS one2014

A high-content, multiplexed screen in human breast cancer cells identifies profilin-1 inducers with anti-migratory activities.

Marion E Joy, Laura L Vollmer, Keren Hulkower, Andrew M Stern, Cameron K Peterson, R C Dutch Boltz, Partha Roy, Andreas Vogt

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Profilin choreographs actin and microtubules in cells and cancer.International review of cell and molecular biology · 2020
    Article
  5. Review
  6. Review
  7. High content analysis in amyotrophic lateral sclerosis.Molecular and cellular neurosciences · 2017
    Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Marion E JoyDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Laura L VollmerUniversity of Pittsburgh Drug Discovery Institute, Pittsburgh, Pennsylvania, United States of America.
Keren HulkowerPlatypus Technologies, LLC, Madison, Wisconsin, United States of America.
Andrew M SternDepartment of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America ; University of Pittsburgh Drug Discovery Institute, Pittsburgh, Pennsylvania, United States of America.
Cameron K PetersonUniversity of Pittsburgh Drug Discovery Institute, Pittsburgh, Pennsylvania, United States of America.
R C Dutch BoltzDepartment of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America ; University of Pittsburgh Drug Discovery Institute, Pittsburgh, Pennsylvania, United States of America.
Partha RoyDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America ; Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America ; Magee Women's Research Institute, Pittsburgh, Pennsylvania, United States of America.
Andreas VogtDepartment of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America ; University of Pittsburgh Drug Discovery Institute, Pittsburgh, Pennsylvania, United States of America.
University of Pittsburgh · USDiscovery Institute · USMagee-Womens Research Institute · USPlatypus Technologies (United States) · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
Profilin as a target to suppress Invasive breast cancerR01CA108607 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ROY, PARTHA · 2006 to 2017
$2.6M
Transformative HTS cell migration assay for rapid screening of cancer therapeuticR21CA147985 · NCI · PLATYPUS TECHNOLOGIES, LLC · PI ACHARYA, BHARAT R, VOGT, ANDREAS · 2010 to 2011
$336k
NCI NIH HHS NIH P30CA047904NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA108607NCI NIH HHS R01CA108607NCI NIH HHS R21 CA147985NCI NIH HHS R21CA147985NIGMS NIH HHS R44GM090368
6 · The paper itself

Abstract

Profilin-1 (Pfn-1) is a ubiquitously expressed actin-binding protein that is essential for normal cell proliferation and migration. In breast cancer and several other adenocarcinomas, Pfn-1 expression is downregulated when compared to normal tissues. Previous studies from our laboratory have shown that genetically modulating Pfn-1 expression significantly impacts proliferation, migration, and invasion of breast cancer cells in vitro, and mammary tumor growth, dissemination, and metastatic colonization in vivo. Therefore, small molecules that can modulate Pfn-1 expression could have therapeutic potential in the treatment of metastatic breast cancer. The overall goal of this study was to perform a multiplexed phenotypic screen to identify compounds that inhibit cell motility through upregulation of Pfn-1. Screening of a test cassette of 1280 compounds with known biological activities on an Oris™ Pro 384 cell migration platform identified several agents that increased Pfn-1 expression greater than two-fold over vehicle controls and exerted anti-migratory effects in the absence of overt cytotoxicity in MDA-MB-231 human breast cancer cells. Concentration-response confirmation and orthogonal follow-up assays identified two bona fide inducers of Pfn-1, purvalanol and tyrphostin A9, that confirmed in single-cell motility assays and Western blot analyses. SiRNA-mediated knockdown of Pfn-1 abrogated the inhibitory effect of tyrphostin A9 on cell migration, suggesting Pfn-1 is mechanistically linked to tyrphostin A9's anti-migratory activity. The data illustrate the utility of the high-content cell motility assay to discover novel targeted anti-migratory agents by integrating functional phenotypic analyses with target-specific readouts in a single assay platform.

Indexed as

Cell MovementAdenineBreast NeoplasmsCell Line, TumorCell Migration AssaysFemaleGene Knockdown TechniquesHigh-Throughput Screening AssaysHumansProfilinsReproducibility of ResultsSmall Molecule LibrariesTyrphostinsAdeninePFN1 protein, humanProfilinsSmall Molecule Librariestyrphostin A9Tyrphostins

Identifiers

PMID24520372
PMCPMC3919756
OpenAlexW2008171078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.